These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 15768377)

  • 41. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M; Chatellier G; Guyene TT; Ménard J
    J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators.
    Bell TP; DeQuattro V; Lasseter KC; Ruff D; Hardison JD; Cushing D; Kezer AE; Michelson EL
    Am J Cardiol; 1999 Jan; 83(2):272-5, A6. PubMed ID: 10073836
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis.
    Pfister M; Schaedeli F; Frey FJ; Uehlinger DE
    Br J Clin Pharmacol; 1999 Jun; 47(6):645-51. PubMed ID: 10383542
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.
    Raasch W; Jöhren O; Schwartz S; Gieselberg A; Dominiak P
    J Hypertens; 2004 Mar; 22(3):611-8. PubMed ID: 15076168
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
    Riegger GA; Bouzo H; Petr P; Münz J; Spacek R; Pethig H; von Behren V; George M; Arens H
    Circulation; 1999 Nov; 100(22):2224-30. PubMed ID: 10577995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
    Cernes R; Mashavi M; Zimlichman R
    Vasc Health Risk Manag; 2011; 7():749-59. PubMed ID: 22241949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
    Kurokawa K; Abe K; Saruta T; Arakawa M; Kikkawa R; Ueda N; Onoyama K; Tomita K; Ogawa N
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):167-75. PubMed ID: 12563567
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
    Naka T; Kubo K; Inada Y; Nishikawa K
    Drug Des Discov; 1999 Aug; 16(2):95-108. PubMed ID: 10533806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia
.
    Katsube Y; Hira D; Tsujimoto M; Koide H; Minegaki T; Ikeda Y; Morita SY; Nishiguchi K; Terada T
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):328-336. PubMed ID: 29792394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension.
    Heuer HJ; Schöndorfer G; Högemann AM
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S55-6. PubMed ID: 9331008
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study.
    Sunami E; Nomura K; Nishiyama Y; Katayama Y
    J Nippon Med Sch; 2016; 83(6):272-276. PubMed ID: 28133009
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.
    Malerczyk C; Fuchs B; Belz GG; Roll S; Butzer R; Breithaupt-Grögler K; Herrmann V; Magin SG; Högemann A; Voith B; Mutschler E
    Br J Clin Pharmacol; 1998 Jun; 45(6):567-73. PubMed ID: 9663812
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Candesartan cilexetil reduces chronic renal allograft injury in Fisher-->Lewis rats.
    Mackenzie HS; Ziai F; Nagano H; Azuma H; Troy JL; Rennke HG; Tilney NL; Brenner BM
    J Hypertens Suppl; 1997 Dec; 15(6):S21-5. PubMed ID: 9493123
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study.
    Asmar R; Nisse-Durgeat S
    Vasc Health Risk Manag; 2006; 2(3):317-23. PubMed ID: 17326337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Candesartan cilexetil: an update.
    Joost A; Schunkert H; Radke PW
    Expert Opin Pharmacother; 2011 Aug; 12(11):1769-80. PubMed ID: 21651457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study.
    Grassi G; Seravalle G; Dell'Oro R; Trevano FQ; Bombelli M; Scopelliti F; Facchini A; Mancia G;
    J Hypertens; 2003 Sep; 21(9):1761-9. PubMed ID: 12923410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impact.
    Bramlage P; Buhck H; Zemmrich C
    Clin Drug Investig; 2014 Apr; 34(4):241-9. PubMed ID: 24482018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
    Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
    Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Candesartan cilexetil in cardiovascular disease.
    Ross A; Papademetriou V
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):829-35. PubMed ID: 15500428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.